Apimeds adds two executives to leadership team

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced the appointment of two executives to its leadership team. Susan Kramer, DrPH, has been named Senior Vice President of Development, and Brian Peters has joined as Head of the company's ai² division.

Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Peters previously served as Chief Strategy & Insights Officer at Heller Agency and held positions at Medexus Pharma, Gilead Sciences, and other healthcare companies.

In her new role, Dr. Kramer will oversee all product development activities at Apimeds. Peters will lead the strategy, positioning, and launch of the company's ai² platform.

Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapeutic. The company is currently developing Apitox as a potential treatment for osteoarthritis knee pain in patients who fail to respond adequately to conservative non-pharmacologic therapy and common analgesics.

Dr. Kramer co-founded Corthera, Inc., which was acquired by Novartis, and has held senior roles at XOMA, Anesiva, and Annexon Biosciences. She holds degrees from the College of St. Scholastica, Central Michigan University, and the University of California, Berkeley.

Peters earned a BA in Communications from Indiana University and previously served as VP of Sales & Marketing at Medexus Pharma from 2013 to 2024.

The information is based on a company press release.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Schwab's May activity shows margin loans nearly double
• Analyst gives SpaceX a rare Sell rating citing execution risks